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Background: Positron emission tomography (PET) scanning with [18 F]fluorodeoxyglucose (18 F-FDG) is a useful
diagnostic and prediction tool in brain tumors, but its value in childhood diffuse intrinsic pontine glioma (DIPG) is
still unclear. For interpretation of 18 F-FDG PET results in DIPG, uptake values of the normal pons of children of
increasing ages are mandatory. The aim of this study was to determine 18 F-FDG standard uptake value ratios (SUVr)
of the normal pons and to compare these to those of DIPG.
Methods: We studied 36 subjects with a normal, non-affected pons (aged 5 to 23 years) and 6 patients with DIPG
(aged 4 to 17 years) who underwent 18 F-FDG PET scanning. Magnetic resonance imaging (MRI) was co-registered
to define the regions of interest. SUVr and SUVrmax for the pons/cerebellum (SUVrp/c) and the pons/occipital lobe
(SUVrp/o) were calculated. Independent-samples t tests and Mann–Whitney U tests were used to compare the mean
SUVr and Pearson’s test for correlations.
Results: For the normal pons, mean SUVrp/c and SUVrp/o were 0.65 (±0.054) and 0.51 (±0.056), respectively. No
significant correlations were found between the SUVr of the normal pons and sex, age, nor pontine volume. A
modest but statistically significant correlation was found between SUVr and post-injection time acquisition timing.
For DIPG, mean SUVrp/c and SUVrp/o were 0.74 (±0.20) and 0.65 (±0.30), respectively, while mean SUVrp(max)/c and
SUVrp(max)/o were 1.95 (±0.48) and 1.81 (±0.20), respectively.
Conclusion: The SUVr of the unaffected pons are strikingly constant between children, irrespective of sex and age,
and can therefore be well used as a reference value for 18 F-FDG PET studies in DIPG.
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Positron emission tomography (PET) scanning with [18 F]
fluorodeoxyglucose (18 F-FDG) provides information on
glucose metabolism. 18 F-FDG PET positively correlates
with an increasing WHO grade in astrocytomas [1]. In
high-grade glioma (HGG), 18 F-FDG PET is an indicator of
response to therapy and is used for PET-guided planning of* Correspondence: mh.jansen@vumc.nl
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in any medium, provided the original work is pstereotactic brain biopsy [2-5]. In the past few years, 18 F-
FDG PET studies have been introduced in diffuse intrinsic
pontine glioma (DIPG) [6-10], a fatal disease that almost
exclusively occurs in children [11]. Interestingly, 18 F-FDG
metabolism in the majority of the DIPG was lower than
that in the non-affected occipital lobe, but increased 18 F-
FDG uptake correlated with decreased overall survival [10].
However, reference values of 18 F-FDG uptake in the nor-
mal pons of children of increasing age are mandatory to
know what increased uptake is in the pons, and these data
are lacking. Therefore, the aim of this study was to calculate
the standard uptake value ratios (SUVr) for the pons/n Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Table 1 Baseline and PET characteristics of controls and
patients with DIPG
Controls DIPG
Number of subjects 36a 6
Male 21 2
Female 15 4
Median age (years) 12 (±4) 6 (±5)
0 to 5 0 2
6 to 10 15 3
11 to 15 14 0
16 to 20 5 1
20 to 25 2 0
Anti-epileptic drugs







Anaplastic astrocytoma 2 (biopsy)
Glioblastoma multiforme 1 (autopsy)
DIPG histology unknown 3
PET characteristics
Mean 18 F-FDG dose (MBq) 187 (±11) 170 (±29)
Mean scan duration (min) 15 (±0) 16 (±2)
15 min 35 5
20 min 1 1
18 F-FDG uptake interval time
Mean (min) 48 (±16) 50 (±27)
PET reconstruction parameters
Method OSEM OSEM
Matrix 256 34 6
Matrix 128 2 0
OSEM, ordered subset expectation maximization. aThe controls consisted of 6
subjects with temporal lobe, 1 with parietal lobe, and 2 with frontal lobe
epileptogenic foci; 5 with hypometabolism of the hippocampus; 5 with focal
cortical dysplasia; 3 with mesial temporal sclerosis; and 14 without structural
or 18F-FDG PET epileptogenic foci.
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(SUVrp/o) in subjects with a normal pons and to investigate
the influence of age, pontine size, and post-injection inter-
val on the SUVr. The SUVr of the normal pons were then
compared to the SUVr and SUVrmax of DIPG.
Methods
Subjects
To study the 18 F-FDG uptake of the normal pons, a retro-
spective cohort was used. Thirty-six children and adoles-
cents aged 6 to 23 years who underwent 18 F-FDG PET
scans for epilepsy surgery planning in the period of 2002
until 2012 were included. All controls had focal epilepsy
and were in a non-ictal state at the moment of scanning.
We inventoried the anti-epileptic agents used at the day
of scanning. We excluded scans that revealed space-
occupying lesions anywhere in the brain or epilepsy-
induced changes in the pons, occipital lobe, and cerebellum
and scans that did not meet the criteria as described under
‘Scanning procedure’. The affected population consisted of
six children with a newly diagnosed DIPG, based on criteria
as described elsewhere from VU University Medical Center
(VUmc), Amsterdam, the Netherlands, who underwent an
18 F-FDG PET scan at diagnosis [11]. The study was ap-
proved by the institutional review board of VUmc.
Scanning procedure
Scans of controls and DIPG patients were performed using
an ECAT EXACT HR+ PET scanner (Siemens/CTI, Knox-
ville, TN, USA), as previously described [12]. Patients and
controls fasted for at least 4 h before the PET scan. Fifteen
minutes before injection, they were positioned in a quiet,
darkened room, with their eyes closed and no noise. After
injection of 185 MBq 18 F-FDG (mean 187.2 MBq ±5.6),
subjects remained in the quiet, darkened room for 35 min
followed by a 10-min 2D transmission scan, acquired using
retractable rotating 68Ge sources, used for attenuation cor-
rection purposes. Approximately 45 min post-injection, a
static 3D emission scan of 15 min was acquired. All emis-
sion scans were reconstructed using ordered subset expect-
ation maximization (OSEM, 4 iterations, 16 subsets) with a
Hanning filter with a cutoff at 0.5 times the Nyquist fre-
quency and included the usual corrections for
normalization, decay, dead time, attenuation, scatter, and
randoms [13]. During reconstruction, a zoom factor of
2.123 and a matrix of 256 × 256 were used, resulting in
voxel sizes of 1.2 × 1.2 × 2.4 mm3. All subjects underwent
structural magnetic resonance imaging (MRI) T1-T2 for
diagnostic purposes. PET characteristics are summarized in
Table 1.
Image analysis
Each patient’s T1-weighted MR image was co-registered to
their 18 F-FDG PET using VINCI software (Max PlanckInstitute, Cologne, Germany) and subsequently used to
manually define the regions of interest (ROIs) of the pons,
occipital lobe, and cerebellum in normal subjects (Figure 1).
For DIPG, the ROI was defined as the hypointense pontine
lesion on T1 MRI, independent of contrast enhancement.
The ROIs were projected on the PET, and the mean uptake
(becquerel per cubic centimeter) was calculated for the en-
tire defined ROI. Next, the SUV ratios were calculated by
dividing the activity (becquerel per cubic centimeter) of the










Figure 1 Co-registered T1-MR and FDG PET of a control. The ROI was defined on the co-registered T1-MR on sagittal, coronal, and axial slices.
The upper row shows the ROI of the pons, the second row of the occipital lobe, and the third row of the cerebellum. For the occipital lobe, five
slices were taken as the ROI from the coronal angle. The lower row shows the PET scan after T1-MRI fusion.
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and cerebellum (SUVrpons/cerebellum = SUVrp/c). Temporo-
parietal lobe was excluded as a reference region in this con-
trol group as FDG uptake may have been affected by
epilepsy-induced changes in this region. For DIPG, the
maximal SUV ratios (SUVrp(max)/c and SUVrp(max)/o) were
calculated by dividing the hottest pixel of the pons (bec-
querel per cubic centimeter) by the mean uptake of the ref-
erence region (becquerel per cubic centimeter). Finally,
SUV ratios were correlated to post-injection time, age, sex,
and pontine volume (calculated on MRI) in the control
cohort.
Statistics
SPSS 18.0 for Windows was used for statistical analyses.
The range and distribution of the SUVrp/c and SUVrp/care illustrated in histograms and boxplots. To determine
whether the observations followed a normal (Gaussian)
distribution, histograms and QQ plots were established.
The mean, standard deviation, and corresponding confi-
dence intervals were calculated accordingly. Based on a
Gaussian distribution in both groups, independent-
samples t tests were used to compare the mean SUV ra-
tios of male versus female subjects. Non-parametric tests
(Mann–Whitney U tests) were used to compare the
SUVr of DIPG versus the SUVr of controls. Pearson’s









































Figure 2 Boxplots of SUVrp/c (a) and SUVrp/o (b) for the normal pons versus DIPG. The SUVr deviation between controls is limited
compared to that between patients with DIPG. The mean SUVrp/c and SUVrp/o are both not significantly higher in DIPG compared to controls. In
the majority of the DIPG patients, the SUVrp/c and SUVrp/o are less than 1.0. Some patients with DIPG even show SUVr at the lower end of the
SUVr of controls.
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Controls showed consistent SUV ratios of the normal
pons: a mean SUVrp/c of 0.65 (±0.054) and a mean
SUVrp/o of 0.51 (±0.056). SUVrp/c and SUVrp/o showed
normal Gaussian distributions as confirmed by histo-
grams and QQ plots (Additional file 1: Figure S1).
Figure 2 shows the SUV ratios of the normal pons.a)
b) c












































Figure 3 Correlation between SUVr and pontine volume, sex, and age
measured on MRI (a). The line shown is the regression curve. The SUVrp/o o
(c). No correlation was found between SUVrp/o and these parameters. ThisPontine SUV ratios in relation to pontine volume, sex,
and age
The average volume of the normal pons was 10 cm3
(±1.4). The pontine volume linearly increased with age
(regression coefficient 0.17, r = 0.51, p = 0.001; Figure 3a).
There was no significant correlation between SUVrp/o
(r = 0.18, p = 0.28; Figure 3b) and pontine volume nor)




















. Age is significantly correlated with the pontine volume of controls as
f controls and DIPG is plotted against pontine volume (b) and age
also applies to SUVrp/c (figures not shown).
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thermore, SUV ratios were found to be age independent,
with r values of −0.17 (p = 0.324) and 0.18 (p = 0.305) for
SUVrp/c and SUVrp/o (Figure 3c), respectively. We also
found no significant difference between male and female
subjects for SUVrp/c (p = 0.86) nor SUVrp/o (p = 0.98).Pontine FDG SUV ratios as a function of post-injection
uptake time
To determine whether uptake time influenced the 18 F-
FDG uptake, we investigated the correlation between the
SUV ratios and the post-injection uptake time in the
control group (Figure 4). A modest positive correlation
was found with both SUVrp/c (r = 0.37, p = 0.034) and
SUVrp/o (r = 0.43, p = 0.012) and increasing post-
injection time. The regression coefficients were small
(0.0011/min and 0.0015/min, respectively).Figure 4 Correlation between SUVr and post-injection (PI) time.
The SUVrp/o (a) and SUVrp/c (b) are plotted against the PI time. Both
SUV ratios slightly increase over time; in other words, the pons
shows a delayed uptake of 18 F-FDG compared to the cerebellum
and occipital lobe. The line shown is the regression curve.18 F-FDG uptake in the normal pons versus DIPG
The average DIPG volume on MRI was 27 cm3 (±4.1).
The mean SUVrp/c in DIPG patients was 0.74 (±0.20),
whereas in controls a SUVrp/c of 0.65 (±0.054) was
found (p = 0.64) (Figure 2). The mean SUVrp/o in DIPG
patients was 0.65 (±0.30), which was 0.51 (±0.056) in
controls (p = 0.37). In only one out of six DIPGs, a
SUVrp/o and SUVrp/c ≥1.0 was found. In three patients
with increased local 18 F-FDG tumor uptake, the SUVr-
max was calculated. The mean SUVrp(max)/o was 1.81
(±0.20) and SUVrp(max)/c was 1.95 (±0.48) which was sig-
nificantly higher than the mean SUVr of the normal
pons (p = 0.042 and p = 0.005).
Discussion
In an era where numerous drug trials in DIPG are on-
going or will be initiated shortly, it is essential to develop
tools to predict disease evolution and to monitor re-
sponse to therapy [14]. 18 F-FDG PET has the potential
to be such a tool. However, the interpretation of 18 F-
FDG PET results in DIPG is hampered by a lack of data
on normal pontine glucose metabolism in children. We
show in this study that 18 F-FDG SUV ratios of the nor-
mal pons versus those of the cerebellum and occipital
lobe are very consistent in between controls, independ-
ent of sex, age, and pontine volume, and are therefore
suitable as a reference value for 18 F-FDG PET studies in
DIPG. Not only the pons of controls but also the pons
infiltrated by tumor often showed lower 18 F-FDG
uptake than the cerebellum and occipital lobe, a
phenomenon that has been reported before [10]. More-
over, the mean SUVr of DIPG were not significantly
higher than those of the normal pons, but this is prob-
ably due to the small DIPG sample size as the standard
deviations were high. One may therefore question the
role of 18 F-FDG PET in DIPG; however, the mean
SUVrmax clearly increased in DIPG compared to the
normal pons. Indeed, a recent study showed a significant
correlation between increased 18 F-FDG tumor uptake
and decreased survival in patients with this disease [10].
This correlation might be even stronger when consider-
ing that a SUVrp/o in DIPG between 0.5 and 1.0 already
reflects increased 18 F-FDG uptake in comparison with
the normal pons. This consideration is not taken into ac-
count in studies using semi-quantitative measurements
that lead to classification as ‘hypo/iso/hypermetabolic’
compared to other brain areas [6-10].
An explanation for the limited 18 F-FDG uptake in DIPG
compared to supratentorial HGG is that DIPGs are hetero-
geneous tumors with a mixed histologic tumor grade, as
local uptake of the tracer is related to the presence of ana-
plastic features [11,15,16]. Calculating the SUVrmax,
reflecting the highest local uptake in the tumor, is helpful in
those tumors with heterogeneous 18 F-FDG uptake. Other
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served integrity of the blood–brain barrier in DIPG and the
presence of white matter in the pontine region, which has
low glucose metabolism [17].
We further investigated whether the time between injec-
tion and PET scanning had an influence on the 18 F-FDG
uptake in the pons of controls compared to other brain
areas. Indeed, SUVrp/c and SUVrp/o were positively corre-
lated with increasing post-injection time. This suggests a
delayed uptake of this tracer in the pons compared to the
cerebellum and occipital lobe. However, the SUVr regres-
sion coefficients were small, and therefore, the influence of
the uptake interval in clinical practice is negligible.
The main advantage of SUV ratios is that the possible er-
rors in the measurement of weight or transcription and
dose administered are minimized by the ratio between the
two SUV measurements [18]. This applies especially for
pediatric cancer, with low patient numbers and therefore
often multi-national multi-center trials. In this study, we
showed that SUV ratios of the normal pons are independ-
ent of sex, pontine volume, and age, although we had an
under-representation of the youngest children (<5 years) in
the control group. Although SUV ratios may give useful in-
formation in serial measurements, they have their limita-
tions. In situations in which the 18 F-FDG uptake of the
reference tissue varies, changes in SUV ratios can be mis-
leading. For example, this may be the case when patients
use steroids, which influence the glucose metabolism of the
brain [19]. A methodological issue in this study was the use
of epilepsy patients as controls, as 18 F-FDG PET data of
healthy children could not be obtained due to ethical rea-
sons regarding radiation exposure. We, however, do not ex-
pect significant changes in glucose metabolism of the pons
due to epilepsy as all our subjects were in an inter-ictal
state, which is not associated with changed glucose
metabolism [20]. Furthermore, several anti-epileptic drugs
including phenobarbital, phenytoin, benzodiazepines, and
valproic acid have been associated with hypometabolism of
the brain and especially the cerebellum and may therefore
overestimate the SUVrp/c. Of these drugs, only valproic acid
and clobazam were used in this study by, respectively, 3
and 4 out of 37 controls [21,22]. The lack of variance in be-
tween controls of both SUVrp/c and SUVrp/o presumes that
the use of anti-epileptic drugs has not influenced our re-
sults significantly. In addition, the use of the cerebellum as
a reference in epileptic patients in 18 F-FDG PET studies is
not uncommon [23,24].
Future 18 F-FDG PET studies in DIPG may now compare
SUVr and SUVrmax in DIPG to the here reported mean
SUV ratios of the normal pons. By comparing SUV ratios
to the normal pons, smaller increases in glucose metabol-
ism can be detected in comparison with semi-quantitative
measurements, as DIPGs often show lower glucose metab-
olism than the reference brain tissue (occipital lobe). In thisway, the sensitivity and applicability of 18 F-FDG PET as a
predictive and response monitoring tool for patients with
DIPG can be increased.
Conclusion
We established a reference SUVr for 18 F-FDG uptake in
the normal pons. SUV ratios are very consistent in between
controls and independent of pontine volume, sex, or age.
Not only was the 18 F-FDG uptake in the normal pons low
compared to that in the reference brain areas, but also the
uptake in DIPG was often lower than that in the occipital
and cerebellar tissues. We encourage a study in controls to
validate our results and propose that future 18 F-FDG PET
trials in DIPG calculate SUV and SUV(max) ratios in order
to relate these to the here reported mean SUV ratios of the
normal pons. Smaller changes in the tumor’s glucose me-
tabolism can be detected in this way, which may have prog-
nostic relevance for the patient.
Additional file
Additional file 1: Figure S1. SUVrp/c and SUVrp/o distributions in
normal controls. Normal Gaussian distributions of both SUVrs are
presented in histograms (a, d) and boxplots (b, e). The Gaussian
distribution was confirmed by QQ plots (c, f).
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